Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Moderna Inc (MRNA)

Moderna Inc (MRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,830,220
  • Shares Outstanding, K 394,587
  • Annual Sales, $ 60,210 K
  • Annual Income, $ -514,020 K
  • 60-Month Beta 0.45
  • Price/Sales 464.26
  • Price/Cash Flow N/A
  • Price/Book 8.92
Trade MRNA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.43
  • Number of Estimates 7
  • High Estimate -0.23
  • Low Estimate -0.95
  • Prior Year -0.37
  • Growth Rate Est. (year over year) -16.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.64 +10.83%
on 09/24/20
81.37 -13.32%
on 10/13/20
+3.37 (+5.02%)
since 09/23/20
3-Month
54.21 +30.11%
on 09/08/20
83.85 -15.89%
on 07/28/20
-4.80 (-6.37%)
since 07/23/20
52-Week
15.52 +354.45%
on 11/01/19
95.21 -25.92%
on 07/17/20
+53.63 (+317.34%)
since 10/23/19

Most Recent Stories

More News
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

Moderna (MRNA) closed at $70.53 in the latest trading session, marking a -0.44% move from the prior day.

MRNA : 70.53 (-0.44%)
Top Analyst Reports for Netflix, Lockheed Martin & Zoetis

Top Analyst Reports for Netflix, Lockheed Martin & Zoetis

ZTS : 163.49 (+0.68%)
TEAM : 208.49 (+2.66%)
NFLX : 488.28 (+0.63%)
MRNA : 70.53 (-0.44%)
LMT : 374.33 (+1.46%)
ITUB : 4.49 (-1.97%)
AstraZeneca (AZN), J&J (JNJ) Coronavirus Trials May Resume Soon

Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.

JNJ : 145.24 (+0.11%)
AZN : 52.00 (+0.08%)
PFE : 38.18 (+2.00%)
MRNA : 70.53 (-0.44%)
Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)

--Moderna thanks PPD, its CRO partner, for the successful execution of COVE Study enrollment

MRNA : 70.53 (-0.44%)
PPD : 35.48 (-1.58%)
5 Stocks Experiencing Increased Volatility in the Past Week

The Presidential election is proving to be a major cause of movement in stocks like: Netflix Inc. (NFLX), First Solar (FSLR), Virgin Galactic (SPCE), General Motors (GM), Moderna Inc. (MRNA). Netflix...

NFLX : 488.28 (+0.63%)
FSLR : 85.37 (+3.29%)
GM : 36.83 (-1.55%)
SPCE : 19.14 (-7.67%)
MRNA : 70.53 (-0.44%)
Next up in hunt for COVID-19 vaccine: Testing shots in kids

The global hunt for a COVID-19 vaccine for kids is only just beginning — a lagging start that has some U.S. pediatricians worried they may not know if any shots work for young children in time for the...

JNJ : 145.24 (+0.11%)
PFE : 38.18 (+2.00%)
MRNA : 70.53 (-0.44%)
4 Biotech Stocks Robinhood Investors Love

The Robinhood app popularity among younger and more-aggressive investors. So, it’s natural they would be interested in biotech given the huge upside of many stocks in the sector. Here are some of the...

EXAS : 109.70 (+2.44%)
MRNA : 70.53 (-0.44%)
MDT : 111.42 (-0.38%)
AMGN : 227.16 (-0.36%)
Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.

PFE : 38.18 (+2.00%)
MRK : 79.83 (+0.78%)
MRNA : 70.53 (-0.44%)
GSK : 35.29 (+0.57%)
Futures to Grow Tuesday

Futures for equities in Canada’s main market rose on Tuesday as oil prices steadied, while optimism ...

MRNA : 70.53 (-0.44%)
2nd Annual Gabelli Funds - Columbia Business School Healthcare Symposium (Virtual)

Join us as we discuss today's pressing healthcare issues.

CVS : 60.25 (+1.29%)
MRNA : 70.53 (-0.44%)
PFE : 38.18 (+2.00%)
REGN : 579.81 (+0.71%)
TDOC : 216.32 (+0.71%)
GBL : 12.63 (-1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA-...

See More

Key Turning Points

2nd Resistance Point 74.18
1st Resistance Point 72.35
Last Price 70.53
1st Support Level 68.75
2nd Support Level 66.98

See More

52-Week High 95.21
Last Price 70.53
Fibonacci 61.8% 64.77
Fibonacci 50% 55.36
Fibonacci 38.2% 45.96
52-Week Low 15.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar